Alphavirus RNA replicon systems

Details Alphavirus RNA replicon systems Alphavirus RNA replicon systems

2007-06-26

2007-06-26

Campell, Bruce R. (Department: 1648)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Genetically modified micro-organism, cell, or virus

C424S218100, C424S199100, C435S235100, C435S236000, C435S239000, C435S325000

Reexamination Certificate

active

10388327

ABSTRACT:
The present invention provides a helper cell for expressing an infectious, replication defective, alphavirus particle in an alphavirus-permissive cell. The helper cell includes (a) a first helper RNA encoding (i) at least one alphavirus structural protein, and (ii) not encoding at least one alphavirus structural protein; and (b) a second helper RNA separate from the first helper RNA, the second helper RNA (i) not encoding the alphavirus structural protein encoded by the first helper RNA, and (ii) encoding the at least alphavirus one structural protein not encoded by the first helper RNA, such that all of the alphavirus structural proteins assemble together into alphavirus particles in the cell. Preferably, the helper cell also includes a replicon RNA encoding an alphavirus packaging sequence and an inserted heterogeneous RNA.

REFERENCES:
patent: 4650764 (1987-03-01), Temin et al.
patent: 5091309 (1992-02-01), Schlesinger et al.
patent: 5185440 (1993-02-01), Davis et al.
patent: 5217879 (1993-06-01), Huang et al.
patent: 5505947 (1996-04-01), Johnston et al.
patent: 5639650 (1997-06-01), Johnston et al.
patent: 5643576 (1997-07-01), Johnston et al.
patent: 5739026 (1998-04-01), Garoff et al.
patent: 5766602 (1998-06-01), Xiong et al.
patent: 5789245 (1998-08-01), Dubensky et al.
patent: 5792462 (1998-08-01), Johnston et al.
patent: 5814482 (1998-09-01), Dubensky, Jr. et al.
patent: 5843723 (1998-12-01), Dubensky, Jr. et al.
patent: 6015694 (2000-01-01), Dubensky et al.
patent: 6190666 (2001-02-01), Garoff et al.
patent: 6224879 (2001-05-01), Sjöberg et al.
patent: 6242259 (2001-06-01), Polo et al.
patent: 6541010 (2003-04-01), Johnston et al.
patent: WO 92/10578 (1992-06-01), None
patent: WO 95/07994 (1995-03-01), None
patent: WO 95/27044 (1995-10-01), None
patent: WO 95/31565 (1995-11-01), None
patent: WO 96/17072 (1996-06-01), None
patent: WO 96/37220 (1996-11-01), None
patent: WO 96/37616 (1996-11-01), None
patent: WO 00/39318 (2000-07-01), None
“Program and Abstracts of the Joint Annual Meeting of the American Society of Tropical Medicine and Hygiene and the American Society of Parasitologists,”Supplement to The American Journal of Tropical Medicine and Hygiene49(3): 195-196 Sep. 1993.
“Sindbis Virus (HRSP and Wild-Type Strains), Complete Genome,”EMBL Database, Accession No. J02363, 02364, J02366, J02367, and V00073, (Jul. 3, 1991).
Bulychyov et al., “Disease Course in Guinea Pigs After Aerogenous Infection with Venezuelan Equine Encaphalomyelits Virs,” (1995).
Frolov et al., “Translation of Sindbis Virus mRNA: Effects of Sequences Downstream of the Initiating Codon,”Journal of Virology, 68 8111-end (1994).
Hahn et al., “Infectious Sindbis Virus Transient Expression Vectors for Studying Antigen Processing and Presentation,”Proc. Natl. Acad. Sci. USA, 89 2679-2683 (1992).
Liljeström, Peter, “Alphavirus Vectors for Gene Delivery,”OECD Documents, Gene Delivery Systems, 109-118 (1996).
London et al., “Infectious Enveloped RNA Virus Antigenic Chimeras,”Proc. Natl. Acad. Sci. USA, 89 207-211 (1992).
Lvov et al., “‘Karshi’ Virus, a New Flavivirus (Togaviridae) Isolated from Ornithodoros Papillipes (Birula, 1895) Ticks in Uzbek S.S.R.,”Archives of Virology, 50 29-36 (1976).
Polo et al. “Molecular Analysis of Sindbis Virus Pathogensis in Neonatal Mice by Using Virus Recombinants Constructed in Vitro”Journal of Virology62: 2124-2133 (1988).
Davis et al. “In Vitro Synthesis of Infectious Venezuelan Equine Encephalitis Virus RNA from a cDNA Clone: Analysis of a Viable Deletion Mutant”Virology181: 189-204 (1989).
Documents from the Opposition filed by Chiron Corporation in the Australian Patent Office against the grant of Australian Patent No. 727036 (Australian Application Serial No. 59256/96) including (i) Notice of Opposition filed by Chiron Corporation dated Feb. 28, 2001.
(ii) Statement of Grounds of Opposition and Particulars Relating to Each Ground Filed by Chiron Corporation dated May 28, 2001.
(iii) Evidence-in-Support filed by Chiron Corporation including Statutory Declaration of Nicholas James Finnie dated May 28, 2002 with Exhibits NJF-1 to NJF-13; Statutory Declaration of John Polo dated Aug. 27, 2002 with Exhibits JP-1 to JP-10; and Statutory Declaration of Alexander A. Khromykh dated Oct. 14, 2002 with Exhibits AK-1 to AK-2.
(iv) Submission by Chiron Corporation to Commissioner of Patents, Australia dated May 11, 2006 advising that the opposition against the grant of Australian Patent No. 727036 is withdrawn.
And (v) Communication issued by IP Australia acknowledging withdrawal of opposition by Chiron Corporation.
Gidwitz et al.; “Differences in virion stability among Sindbis virus pathogenesis mutants”,Virus Research, 10 (1988) 225-240.
Johnston et al.; “Selection for Accelerated Penetration in Cell Culture Coselects for Attenuated Mutants of Venezuelan Equine Encephalitis Virus”,Virology, 162, (1988) 437-443.
Johnston et al.; “Studies of Alphavirus Virulence Using Full-Length Clones of Sindbis and Venezuelan Equine Encephalitis Viruses”, M.A. Brinton et al. (eds), New Aspects of Positive Strand RNA Viruses, pp. 334-339 (1990) ASM Press.
Kaufman et al.; “Improved vectors for stable expression of foreign genes in mammalian cells by use of the untranslated leader sequence from EMC virus”,Nucleic Acids Research, 19 (16) (1991) 4485-4490.
Olmstead et al.; “Sindbis Virus Mutants Selected for Rapid Growth in Cell Culture Display Attenuated Virulence in Animals”,Science, 225, (1984) 424-427.
Polo et al.; “A Model for In Vitro Development of Live, Recombinant Alphavirus Vaccines”, Vaccines 90: Modern Approaches to New Vaccines Including Prevention of AIDS, pp. 105-108 (1990). Brown et al. (eds) (old Spring Harbor Laboratory).
Polo et al.; “Mutational Analysis of Virulence Locus in the E2 Glycoprotein Gene of Sindbis Virus”,Journal of Virology, 65 (11), (1991) 6358-6361.
Presley et al; “Proteolytic Processing of the Sindbis Virus Membrane Protein Precursor PE2 is Nonessential for Growth in Vertebrate Cells but it Required for Efficient Growth in Invertebrate Cells”,Journal of Virology, 65 (4), (1991) 1905-1909.
Cheng Xiong, et al. “Sindbis Virus: An Efficient, Broad Host Range Vector for Gene Expression in Animal Cells.”Science, New Series, vol. 243, Issue 4895 (Mar. 3, 1989), 1188-1191.
Ute Geigenmuller-Gnirke, et al. “Complementation Between Sindbis Viral RNAs Produces Infectious Particles with a Bipartite Genome.”Proceedings of the National Academy of Sciences of the United States of America, vol. 88, Issue 8 (Apr. 15, 1991), 3253-3257.
Barbara G. Weiss and Sondra Schlesinger. “Recombination between Sindbis Virus RNAs.”Journal of Virology. vol. 65, No. 8 (Aug. 1991), 4017-4025.
Sondra Schlesinger. “Alphaviruses—vectors for the expression of heterologous genes.”TiBTech. (1993), 18-22.
Richard M. Kinney. “Attenuation of Venezuelan Equine Encephalitis Virus Strain TC-83 Is Encoded by the 5′-Noncoding Region and the E2 Envelope Glycoprotein.”Journal of Virology. vol. 67, No. 3, (Mar. 1993), 1269-1277.
N.L. Davis. “A molecular genetic approach to the study of Venezuelan equine encephalitis virus pathogenesis.”Archives of Virology. (1994), 99-109.
E. Mathilda Sjöberg, et al. “A Significantly Improved Semliki Forest Virus Expression System Based on Translation Enhancer Segments from the Viral Capsid Gene.”Bio/Technology. vol. 12, (Nov. 1994), 1127-1131.
Peter Liljeström. “Alphavirus expression systems.”Current Opinion in Biotechnology. vol. 5, No. 5, (Oct. 1994), 495-500.
S. Schlesinger and B.G. Weiss. “Recombination between Sindbis virus RNAs.”Archives of Virology. Suppl. 9, (1994), 213-220.
Bredenbeek et al, Sindbis Birus Expression Vectors: Packaging of RNA Repl

Affiliated with

Also associated with

Rating

Alphavirus RNA replicon systems does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Alphavirus RNA replicon systems, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Alphavirus RNA replicon systems will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3854818